

ASX / MEDIA ANNOUNCEMENT

17 April 2020

Bi-monthly update – conference call

**Respiri Limited (ASX:RSH) (“Respiri” or the “Company”)**, an eHealth SaaS Company supporting respiratory health management, is holding a conference call to provide shareholders, potential investors and analysts an update of the Company’s operations over the past two months.

The conference call will be held via Zoom on Tuesday April 21<sup>st</sup>, 2020 at 11am.

Dial in details are shown below.

Topic: Respiri Limited Shareholder Update  
Time: Apr 21, 2020 11:00 AM Canberra, Melbourne, Sydney

Join Zoom Meeting  
<https://zoom.us/j/99221808976>

Meeting ID: 992 2180 8976

Dial by your location  
+61 8 7150 1149 Australia  
+61 2 8015 6011 Australia  
+61 3 7018 2005 Australia  
+61 731 853 730 Australia  
+61 861 193 900 Australia  
+64 4 886 0026 New Zealand  
+64 9 884 6780 New Zealand

We look forward to speaking with you on Tuesday and providing you with an update of the Company’s operations along with confirmation of our major achievements - versus plans – and an outline of the future roadmap to commercialisation. Please forward any questions to the following email address beforehand [info@respiri.co](mailto:info@respiri.co)

The conference call will be recorded. A copy will be made available on the Company’s website after the meeting.

- ENDS -

For further information, investors and media please contact:

**Mr Marjan Mikel**  
CEO & Managing Director  
Respiri Limited  
P: +61 408 462 873  
E: [marjan@respiri.co](mailto:marjan@respiri.co)

**Mr Nicholas Smedley**  
Executive Chairman  
Respiri Limited  
P: +61 447 074 160  
E: [nicholas@respiri.co](mailto:nicholas@respiri.co)

*This ASX announcement dated 17 April 2020 has been authorised for release by the Board of Directors of Respiri Limited.*

## About Respiro Limited

Respiro is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. The only platform of its kind, the flagship wheezo® product employs machine learning to provide personalised feedback and education based on the user's personal health data correlated with environmental factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.

Respiro's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiro Limited's operations are based in Melbourne, Australia.

For additional information about Respiro and its products, please visit [www.respiro.co](http://www.respiro.co)

## Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respiro current expectations, estimates and projections about the industry in which Respiro operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiro, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respiro cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respiro only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiro will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.